ClinicalTrials.gg
CompletedNCT00952822Updated May 24, 2021Results posted

Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection

A Phase 1 interventional study of Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII) in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 11 sites in United States. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-24.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Aug 2008, registered Aug 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
2 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
8th of 21
52 · median 50
Started
2008
the only one that year
Phase 1
3 of 21
none open now
Registered
7th of 21
by date
Lead sponsor
8 of 21
Baxalta now part of Shire

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 8th largest by enrollment, is the only one that started in 2008, is one of 3 in phase 1, and was the 7th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 2 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of this study is to determine the pharmacokinetics and safety of Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) reconstituted in 2 mL sterile water for injection (SWFI) and compare with those of rAHF-PFM reconstituted in 5 mL of SWFI.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject or subject's legally authorized representative has provided written
  • The subject has severe hemophilia A as defined by a baseline FVIII activity \<= 1% of normal; tested at screening
  • The adolescent/adult subject has a documented history of at least 150 exposure days to FVIII concentrates (either plasma-derived or recombinant), and the pediatric subject has at least 50 exposure days
  • The subject is >= 12 to \<= 65 years of age for the complete pharmacokinetic assessment and >= 2 to \< 12 years for the incremental recovery assessment The subject has a performance score > 60
  • The subject is negative (HIV-) or HIV+ with stable >= 200 cells/mm³ (CD4 count determined at screening, if necessary)

Exclusion criteria

Exclusion Criteria:

  • The subject has a known to mouse or hamster proteins or to FVIII concentrates
  • The subject has a history of FVIII inhibitors with titer >= 0. 5 BU (Bethesda Assay) or >= 0.4 BU (Nijmegen modification of the Bethesda Assay) any time prior to screening
  • The subject has a detectable FVIII inhibitor at screening, >= 0.4 BU (Nijmegen modification of the Bethesda Assay), in the central laboratory
  • The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices
  • The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (e.g. qualitative defect or Von Willebrand Disease)
  • The subject has received another product within 30 days of enrollment
  • The subject's clinical condition may require major or moderate surgery (estimated blood loss > 500 mL) during the period of participation in the study
  • Subjects with medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance
  • The subject is a female of with a positive pregnancy test at screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    1

    ADVATE reconstituted in 2 mL sterile water for infusion

    Biological: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)

  • Active comparator
    2

    ADVATE reconstituted in 5 mL sterile water for infusion

    Biological: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve

    Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

Secondary outcomes

  1. Total Area Under the Curve

    Total AUC when the concentration is extrapolated to zero using the slope of the β-phase of the model

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  2. Adjusted in Vivo Incremental Recovery

    Increase in factor VIII concentration from pre- to post-infusion

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion

  3. Terminal Half-life

    Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  4. Weight-Adjusted Clearance

    Computed as the weight-adjusted dose divided by total AUC

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  5. Mean Residence Time

    Computed as total area under the moment curve divided by the total AUC. Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  6. Volume of Distribution at Steady State

    Computed as weight-adjusted clearance \* mean residence time

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  7. Maximum Plasma Concentration

    Maximal factor VIII concentration post-infusion

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  8. Number and Severity of Infusion Site Reactions

    Infusion-related local reactions (including pain, tenderness, erythema, induration, and bruising) and severity were evaluated according to an FDA-defined grading scale (FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007).

    Time frame: Within 5 minutes pre-infusion up to 24 hours post-infusion

  9. Infusion Site Pain

    Pain was assessed by participants (≥5 years of age) on a visual analog scale (VAS) from 0 (no pain) to 100 (worst possible pain).

    Time frame: Within 5 minutes post-infusion up to 24 hours post-infusion

07

Results

Posted Jul 21, 2011

Participant flow

Enrollment was conducted in the United States at 11 sites. Two cohorts were recruited (adolescent/adults aged ≥12 to ≤65 years and pediatrics aged ≥2 to \<12 years).

1st Pharmacokinetic Evaluation
Participant flow — 1st Pharmacokinetic Evaluation
MilestoneAdolescents/Adults - 2 mL Then 5 mLAdolescents/Adults - 5 mL Then 2 mLPediatrics - 2 mL Then 5 mLPediatrics - 5 mL Then 2 mL
Started918114
Completed917114
Not completed0100
Withdrew: Lost to follow-up0100
2nd Pharmacokinetic Evaluation
Participant flow — 2nd Pharmacokinetic Evaluation
MilestoneAdolescents/Adults - 2 mL Then 5 mLAdolescents/Adults - 5 mL Then 2 mLPediatrics - 2 mL Then 5 mLPediatrics - 5 mL Then 2 mL
Started917114
Completed917104
Not completed0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryArea Under the Curve

Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Geometric mean · IU*h/dL
Area Under the Curve
IU*h/dLAdolescents/Adults - 2 mLAdolescents/Adults - 5 mL
Area Under the Curve1257.20 ± 380.601297.42 ± 487.57
Statistical analysis
  • Adolescents/Adults - 2 mL vs Adolescents/Adults - 5 mL · Difference of least-squares means: -0.052 · 90% CI -0.117 to 0.012
SecondaryTotal Area Under the Curve

Total AUC when the concentration is extrapolated to zero using the slope of the β-phase of the model

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Geometric mean · IU*h/dL
Total Area Under the Curve
IU*h/dLAdolescents/Adults - 2 mLAdolescents/Adults - 5 mL
Total Area Under the Curve1357.60 ± 436.241368.12 ± 553.21
Statistical analysis
  • Adolescents/Adults - 2 mL vs Adolescents/Adults - 5 mL · Difference of least-squares means: -0.016 · 90% CI -0.076 to 0.043
SecondaryAdjusted in Vivo Incremental Recovery

Increase in factor VIII concentration from pre- to post-infusion

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion
Reported as:
Geometric mean · IU/dL:IU/kg
Adjusted in Vivo Incremental Recovery
IU/dL:IU/kgAdolescents/Adults - 2 mLAdolescents/Adults - 5 mLPediatrics - 2 mLPediatrics - 5 mL
Adjusted in Vivo Incremental Recovery1.87 ± 0.341.88 ± 0.401.33 ± 0.361.66 ± 0.25
SecondaryTerminal Half-life

Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Mean · hours
Terminal Half-life
hoursAdolescents/Adults - 2 mLAdolescents/Adults - 5 mL
Terminal Half-life12.54 ± 3.8012.50 ± 2.89
SecondaryWeight-Adjusted Clearance

Computed as the weight-adjusted dose divided by total AUC

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Mean · mL/(kg*h)
Weight-Adjusted Clearance
mL/(kg*h)Adolescents/Adults - 2 mLAdolescents/Adults - 5 mL
Weight-Adjusted Clearance3.85 ± 0.953.81 ± 1.20
SecondaryMean Residence Time

Computed as total area under the moment curve divided by the total AUC. Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Mean · hours (h)
Mean Residence Time
hours (h)Adolescents/Adults - 2 mLAdolescents/Adults - 5 mL
Mean Residence Time14.79 ± 5.2414.34 ± 4.27
SecondaryVolume of Distribution at Steady State

Computed as weight-adjusted clearance \* mean residence time

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Mean · dL/kg
Volume of Distribution at Steady State
dL/kgAdolescents/Adults - 2 mLAdolescents/Adults - 5 mL
Volume of Distribution at Steady State0.54 ± 0.130.51 ± 0.13
SecondaryMaximum Plasma Concentration

Maximal factor VIII concentration post-infusion

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Geometric mean · IU/dL
Maximum Plasma Concentration
IU/dLAdolescents/Adults - 2 mLAdolescents/Adults - 5 mL
Maximum Plasma Concentration102.77 ± 19.35106.46 ± 17.95
SecondaryNumber and Severity of Infusion Site Reactions

Infusion-related local reactions (including pain, tenderness, erythema, induration, and bruising) and severity were evaluated according to an FDA-defined grading scale (FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007).

Time frame:
Within 5 minutes pre-infusion up to 24 hours post-infusion
Reported as:
Number · Participants
Number and Severity of Infusion Site Reactions
ParticipantsAdolescents/Adults - 2 mLAdolescents/Adults - 5 mLPediatrics - 2 mLPediatrics - 5 mL
Pain- Mild (Grade 1)0000
Pain- Moderate (Grade 2)0000
Pain- Severe (Grade 3)0000
Pain- Potentially Life Threatening (Grade 4)0000
Tenderness- Mild (Grade 1)0000
Tenderness- Moderate (Grade 2)0000
Tenderness- Severe (Grade 3)0000
Tenderness- Potentially Life Threatening (Grade 4)0000
Erythema- Mild (Grade 1)0000
Erythema- Moderate (Grade 2)0000
Erythema- Severe (Grade 3)0000
Erythema- Potentially Life Threatening (Grade 4)0000
Induration- Mild (Grade 1)0010
Induration- Moderate (Grade 2)0000
Induration- Severe (Grade 3)0000
Induration- Potentially Life Threatening (Grade 4)0000
Bruising- Mild (Grade 1)0010
Bruising- Moderate (Grade 2)0000
Bruising- Severe (Grade 3)0000
Bruising- Potentially Life Threatening (Grade 4)0000
SecondaryInfusion Site Pain

Pain was assessed by participants (≥5 years of age) on a visual analog scale (VAS) from 0 (no pain) to 100 (worst possible pain).

Time frame:
Within 5 minutes post-infusion up to 24 hours post-infusion
Reported as:
Median · Scores on a scale
Infusion Site Pain
Scores on a scaleAdolescents/Adults - 2 mLAdolescents/Adults - 5 mLPediatrics at Least 5 Years of Age - 2 mLPediatrics at Least 5 Years of Age - 5 mL
Within 5 minutes (immediately) after infusion0 (0 to 12)0 (0 to 27)8 (0 to 37)4 (0 to 61)
60 ± 5 minutes after infusion0 (0 to 3)0 (0 to 4)2.5 (0 to 66)1 (0 to 7)
6 hours ± 30 minutes after infusion0 (0 to 3)0 (0 to 2)0 (0 to 8)0 (0 to 4)
24 hours after infusion0 (0 to 2)0 (0 to 3)0 (0 to 8)0 (0 to 2)

Adverse events

Collected over During course of study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adolescents/Adults—0/27 (0%)1/27 (3.7%)
Pediatrics—1/15 (6.7%)10/15 (66.7%)
Most frequent serious events
Most frequent serious events
EventAdolescents/AdultsPediatrics
PyrexiaGeneral disorders0/271/15
Most frequent other events
Most frequent other events
EventAdolescents/AdultsPediatrics
ContusionInjury, poisoning and procedural complications1/275/15
Arthropod biteInjury, poisoning and procedural complications1/272/15
Allergy to arthropod stingImmune system disorders0/271/15
Catheter thrombosisGeneral disorders0/271/15
Conjunctival hemorrhageEye disorders0/271/15
Ear infectionInfections and infestations0/271/15
HemarthrosisMusculoskeletal and connective tissue disorders0/271/15
Injection site hematomaGeneral disorders0/271/15
Injection site swellingGeneral disorders0/271/15
Joint range of motionMusculoskeletal and connective tissue disorders0/271/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treated Participants
Pediatrics6 ± 3
Adolescents/Adults26 ± 10
Age, Customized
Age, Customized(Participants)Treated Participants
≥2 to <12 years (Number Pediatrics)15
≥12 to <16 years (Number Adolescents)3
≥16 to 65 years (Number Adults)24
Sex: Female, Male
Sex: Female, Male(Participants)Treated Participants
Female0
Male42
Region of Enrollment
Region of Enrollment(Participants)Treated Participants
United States42
08

Study locations

11 sites
  • Washington, District of Columbia, United States
  • Atlanta, Georgia, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Detroit, Michigan, United States
  • New Brunswick, New Jersey, United States
  • New York, New York, United States
  • Cincinnati, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Houston, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2008 to primary completion in Oct 2009, 14 months.

Results were first posted in Jul 2011, 1 year 8 months after primary completion.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 14 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2009
First posted
Aug 6, 2009
StartActual
Aug 8, 2008
Primary completionActual
Oct 23, 2009
CompletionActual
Oct 23, 2009
Results first posted
Jul 21, 2011
Last update
May 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00952822
Responsible party
Sponsor
First posted
Aug 6, 2009
Start date
Aug 8, 2008
Primary completion
Oct 23, 2009
Completion
Oct 23, 2009
Results posted
Jul 21, 2011
Last update
May 24, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antihemophilic factor, human recombinant

Start the discussion